STO:HNSA
Hansa Biopharma AB (publ) · STO · Healthcare · SEK · FY for 2025
Figures on this page computed 2026-11-08 12:41 UTC
Last close
n/aSEK
Market data
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-240.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
-247.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
Price is the furthest below its sector's middle: 0.09 against 0.31 on the market's range.
- Growth105.3%83 of 100, above its sector
- Returns on capital-45.8%13 of 100, below its sector
- Margins62.4%27 of 100, below its sector
- Price14.4x9 of 100, below its sector
- Safety1.9432 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Nothing in our coverage is near enough to this company to compare it with, so we are not comparing it with anything.
Nothing is drawn in its place. The other lenses are unaffected.
We hold no market value we can defend for STO:HNSA, so there is no size to find companies near.